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Background: Alectinib is an approved treatment for anaplastic lymphoma kinase (ALK)-
positive patients with advanced non-small-cell lung cancer. Despite positive supporting clinical 
data, there is a lack of real-world information on the usage and patient outcomes of those treated 
with alectinib post-crizotinib progression.
Methods: Participating oncologists (N=95) in the USA were recruited from an online physician 
panel to participate in a retrospective patient chart review. Physicians randomly selected eligible 
patients (ie, patients who progressed on crizotinib as their first ALK inhibitor and were treated 
with alectinib as their second ALK inhibitor), collected demographics and clinical history from 
their medical charts, and entered the data into an online data collection form.
Results: A total of N=207 patient charts were included (age: 60.1±10.4 years; 53.6% male). 
The patients in our sample were older (median age of 60 vs 53 years), were more likely to be 
current smokers (12% vs 1%), had better performance status (45% vs 33% had an Eastern 
Cooperative Oncology Group [ECOG] of 0), and were less likely to have an adenocarcinoma 
histology (83% vs 96%) relative to published clinical trials. The objective response rate was 
higher than in clinical trials (67.1% vs 51.3%, respectively) as was the disease control rate 
(89.9% vs 78.8%, respectively), though it varied by race/ethnicity, ECOG, and prior treat-
ment history. Discontinuation (0.0%) and dose reductions (3.4%) due to adverse events were 
uncommon in alectinib.
Conclusion: Patients using alectinib post-crizotinib in clinical practice are older, more racially/
ethnically and histologically diverse than patients in published trials. Real-world response rates 
were high and similar to those reported in clinical studies, though there is some variation by 
patient characteristics. Alectinib was well tolerated in clinical practice as reflected by the rates 
of discontinuation, dose reductions, and dose interruptions.
Keywords: alectinib, anaplastic lymphoma kinase, non-small-cell lung cancer, treatment pat-
terns, outcomes, ALK inhibitor, ALK+
Introduction
An estimated 220,000 adults were diagnosed with lung and bronchus cancer in the 
USA in 2015, representing 13% of all new cancer cases.1 Non-small-cell lung cancer 
(NSCLC) accounts for ~80%–85% of all cases of lung cancer, and is the most com-
mon cause of death in men and second only to breast cancer in women.2 Prognosis is 
poor for patients with metastatic disease, with the median survival ,1 year because 
of delays in diagnosis.3,4
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Treatment of NSCLC is guided by disease stage, histol-
ogy, and mutation status. Surgery is the most common treat-
ment for early-stage localized disease, whereas multimodal 
therapy remains the norm for patients with locally advanced 
disease.5 Approximately 40% of patients with NSCLC present 
with metastatic or locally advanced disease, underscoring the 
importance of identifying therapeutic regimens that may benefit 
this large patient population. Combination chemotherapy, 
usually platinum-based, has historically been the first-line 
therapy of choice for advanced NSCLC among patients without 
driver mutations.6–8 Newer agents, such as programmed cell 
death-1 and programmed cell death ligand-1 inhibitors, 
have been more recently evaluated in clinical trials for the 
treatment of NSCLC and several other types of cancer.9–11
Over the last decade, a variety of targeted therapies have 
been developed for the treatment of advanced or metastatic 
NSCLC in patients with driver mutations. Indeed, anaplastic 
lymphoma kinase (ALK) inhibitors represent a promising 
potential target for antitumor therapy,12–14 with ~2%–7% of 
patients with NSCLC being ALK positive.7,15 Crizotinib was 
identified as the first potent inhibitor of ALK in experimental 
cancer models;16 clinical data have suggested superior 
response and longer progression-free survival for patients 
treated with crizotinib relative to chemotherapy.17–20
Despite these efficacy results, almost all patients ulti-
mately develop resistance to crizotinib within 1–2 years, 
with the central nervous system (CNS) being a frequent site 
of progression.21–24 The recently available second-generation 
ALK inhibitors (eg, ceritinib, alectinib, brigatinib) and third-
generation ALK inhibitors (eg, lorlatinib) have been found 
to provide significant benefits for patients who experience 
crizotinib progression.25,26 Of the second-generation ALK 
inhibitors, alectinib is the only one that is not exported 
out of the CNS because of it not being a p-glycoprotein 
substrate,25–27 and several clinical studies28–31 have shown 
alectinib to be highly active, especially in patients with 
brain metastases and CNS disease. Further, alectinib is well 
tolerated among crizotinib-resistant patients.28–31 However, 
little real-world data exist on the usage and outcomes of 
patients treated with alectinib after crizotinib progression. 
The aim of the present study is to examine the real-world 
treatment patterns and clinical outcomes of patients with 
ALK+ NSCLC who have progressed on crizotinib and were 
treated with alectinib as their second ALK inhibitor.
Methods
Data source
A retrospective patient chart review study was conducted to 
meet the objectives described above. Participating oncologists 
were recruited from the Medefield physician panel (http://
www.medefield.com/). The Medefield panel is an opt-in 
panel in which physicians join with the understanding that 
they will complete periodic surveys. All panel physicians 
in the USA have their credentials validated with American 
Medical Association.
Potential physician respondents were emailed an invitation 
to participate in the study. Physicians who provided informed 
consent were screened for eligibility. Physicians’ inclusion 
criteria include board-certified or board-eligible oncologist, 
in practice for at least 5 years but no more than 25 years, 
personally involved in the treatment decisions of patients with 
NSCLC, and have seen at least 1 NSCLC ALK+ patient in 
the past year. Physicians who met inclusion criteria were then 
asked to select between 1 and 5 of their patient charts that met 
the following eligibility criteria: $18 years, diagnosed with 
ALK+ NSCLC (tumors harboring a rearranged ALK gene/
fusion protein), and experienced disease progression while 
on crizotinib (as their first ALK inhibitor). ALK+ status was 
determined by the responding physician based on results avail-
able in the patient chart. It was desired to have a minimum of 
12-month follow-up from time of initial disease progression 
on crizotinib or until death (if ,12 months of follow-up exist). 
Patients who participated in an NSCLC-related clinical trial 
prior to crizotinib and alectinib were excluded.
Using the data available from each medical chart, the 
physician collected the demographics, health history, health 
care resource use, and treatment information for each patient. 
Data were pulled from notes from physical examinations, 
laboratory data, imaging data, prescription data, and nurse 
records, as appropriate.
ethics
The study protocol and data collection form were reviewed 
by an independent institutional review board (Pearl IRB, 
Indianapolis, IN; Protocol #: 16-033202) and the study was 
granted exemption status. The IRB reviewed the documents 
submitted for exemption determination in accordance to the 
US Food and Drug Administration 21 CFR 56.104 and the 
Department of Health and Human Services 45 CFR 46.101 
regulations.. The exemption was approved under the exempt 
review category 45 CFR 46.101(b) category 4.
Patient written informed consent to review the medical 
records was not required by the IRB as no personally iden-
tifiable patient information was collected. Only anonymous 
patient data were collected and results were only reported in 
aggregate. Physicians provided consent for participating in the 
study and written informed consent was required from each 
responding physician, before participating in the study.
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study sample
Data from a total of N=207 patient charts who used alectinib 
as their second ALK inhibitor were collected from N=95 
physicians.
study measures
Physician demographics: Physicians provided information 
as to their age, sex, and practice characteristics (years in 
practice, setting, and patient load).
Patient demographics: Physicians provided information 
related to the age, sex, and employment status of each patient.
General health history: Height and weight (to convert 
to body mass index [BMI] category), smoking history, and 
comorbidities (to calculate a Charlson comorbidity index) 
were assessed.
NSCLC history: The date of diagnosis, stage at diagnosis, 
histology, current performance status (Eastern Cooperative 
Oncology Group [ECOG]), and the number/location/date of 
metastases were captured.
Treatment history: Treatments used prior to and after 
crizotinib, including their duration, were captured. Reasons 
for discontinuation of each therapy were captured along with 
the presence and reasons for dose modifications. The pres-
ence of adverse events was captured along with treatments 
related to brain/CNS metastases.
Clinical outcomes: Best response (complete response 
[CR], partial response [PR], stable disease [SD], or progres-
sion) was captured for each treatment based on the inter-
pretation of the treating physician using the data contained 
within the medical chart. The study did not mandate that 
any specific criteria, such as RECIST v1.1, were to be used 
in this assessment. For the purposes of this study, objective 
response rate (ORR) was defined as the proportion of patients 
achieving a best response of CR or PR. Disease control rate 
(DCR) was defined as the proportion of patients achieving 
a best response of CR, PR, or SD.
Health care resource use: The number of hospitaliza-
tions, emergency room visits, and office visits was captured. 
Health care resource use specific to adverse events was 
also assessed.
statistical analysis
Physician and patient characteristics, response rates, and 
safety/tolerability were reported descriptively using frequen-
cies and percentages for categorical variables and means and 
standard deviations for continuous variables. Differences 
in response rates across patient characteristic strata were 
compared using chi-square tests.
Results
Physician characteristics
A total of N=95 physicians contributed patient charts; N=47 
(49.5%) specialized in hematology/oncology and N=48 
(50.5%) specialized in medical oncology (Table 1). Physi-
cians were predominantly male (81.1%), with a mean of 
14.6 years (SD =6.4) in practice. The most common practice 
setting was private practice (46.3%) followed by an academic 
hospital/medical center (35.8%).
real-world vs clinical trial patient 
characteristics
Descriptive comparisons were then made between our 
study and available clinical trial results (Table 2).28,29 Key 
differences observed between our study and clinical trial 
populations included age (median age of 60 vs 53 for our 
study and the pooled clinical trial samples, respectively), 
gender (54% vs 44% male, respectively), and performance 
status (45% vs 33% had an ECOG of 0). Both our study 
and clinical trial samples had similar percentages of Asian 
patients (18% vs 19%). Patients in our study were more 
likely to be a current smoker (12% vs 1%), less likely to 
have an adenocarcinoma histology (83% vs 96%), and were 
less likely to have presented with brain metastases (12% vs 
60%) relative to clinical trial samples.
Comparisons were also made between alectinib best 
overall responses rates in our study and clinical trial data 
(Table 3). Among the full sample (N=207 alectinib patients), 
Table 1 characteristics of the physician sample treating patients 
with alectinib post-crizotinib progression (n=95)
Characteristics Total sample 
(N=95)
Physician gender
Male (%) 77 (81.1)
Female (%) 18 (18.9)
Physician age
,40 years (%) 19 (20.0)
41–50 years (%) 49 (51.6)
51–60 years (%) 22 (23.2)
61–70 years (%) 5 (5.3)
Physician specialty
Medical oncology (%) 47 (49.5)
hematology/oncology (%) 48 (50.5)
Years of practice in specialty
Mean ± standard deviation 14.6±6.4
Median (min–max) 15 (5.0–30.0)
Primary clinical practice
Private practice (%) 44 (46.3)
academic hospital/medical center (%) 34 (35.8)
nonacademic hospital/medical center (%) 10 (10.5)
comprehensive cancer center (%) 7 (7.4)
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the ORR was higher than in clinical trials (67.1% vs 
51.3%, respectively) as was the DCR (89.9% vs 78.8%, 
respectively).
Best overall response rates in the overall alectinib sub-
sample were then compared across various patient char-
acteristic strata (Table 4). As reported above, best overall 
response rates were consistent, and in some cases higher than 
those reported in prior clinical trials.28,29 Although response 
did not differ by physician characteristics or patient age, 
ORR was highest among Asian respondents (89.2%) vs 
47.4% among non-Asian/non-White respondents (P,.05). 
These findings are consistent with those reported in clinical 
trials.28,29 Former/passive/never smokers exhibited higher 
response rates relative to current smokers (ORR =68.3% 
vs 58.3%) but this difference was not significant (P=0.07). 
No differences were observed by level of BMI (P=0.81). 
Better functional status, as assessed by ECOG performance 
score, was associated with better response (ORR =71.6% 
for ECOG 0–1 vs 30.0% for ECOG 2+; P,0.05). Finally, 
ORR was similar between those with and without prior 
chemotherapy (65.9% vs 67.5%, respectively); however, 
rates of SD were higher (25.8% vs 11.4%) and rates of PD 
were lower (6.7% vs 22.7%) for those without prior chemo-
therapy (P,0.05).
Dose modifications
The median dose for the patients in this study was 600 mg 
twice daily. Discontinuations were the most common cat-
egory of dosage modification. Among those who used 
alectinib, 14.0% of patients (N=29) discontinued the drug, 
whereas only 4.3% (N=9) had their dose reduced; and only 
one patient experienced a dose interruption (N=1; 0.5% 
Table 2 Differences in patient characteristics between clinical trial samples and the current study sample among those using alectinib 
post-crizotinib progression
Characteristics Alectinib group  
in Ou et al28
Alectinib group  
in Shaw et al29
Pooled analysis 
in Yang et al30
Alectinib group 
in study sample
n 138 87 225 207
Patient age (years)
Mean ± standard deviation 51.5±11.1 n/a n/a 60.1±10.4
Median (min–max) 52.0 (22.0–79.0) 54.0 (29.0–79.0) 53.0 (22.0–79.0) 60 (25–86)
sex
Male (%) 61 (44) 39 (45) 100 (44) 111 (53.6)
Female (%) 77 (56) 48 (55) 125 (56) 96 (46.4)
race/ethnicity
non-hispanic White/caucasian (%) 93 (67) 73 (84) 166 (74) 113 (54.6)
asian (%) 36 (26) 7 (8) 43 (19) 37 (17.9)
non-hispanic Black/african american (%) 4 (2) 29 (14.0)
hispanic (%) 25 (12.1)
Other (%) 9 (7) 7 (8) 12 (5) 3 (1.5)
smoking status
current smoker (%) 3 (2) 0 (0) 3 (1) 24 (11.6)
Former smoker (%) 39 (28) 33 (38) 72 (32) 86 (41.6)
never smoker (%) 96 (70) 54 (62) 150 (67) 81 (39.1)
Passive (second-hand) smoker (%) 0 (0) 0 (0) 0 (0) 13 (6.3)
Unknown (%) 0 (0) 0 (0) 0 (0) 3 (1.5)
nsclc histological subtype
adenocarcinoma (%) 133 (96) 82 (94) 215 (96) 172 (83.1)
epidermoid or squamous cell carcinoma (%) 2 (1) 5 (6) 10 (4) 11 (5.3)
large cell carcinoma (%) 3 (2) 16 (7.7)
ecOg at crizotinib initiation
0 (%) 44 (32) 30 (35) 74 (33) 94 (45.4)
1 (%) 81 (59) 48 (55) 129 (57) 84 (40.6)
2 (%) 13 (9) 9 (10) 22 (10) 18 (8.7)
3 (%) 0 (0) 0 (0) 0 (0) 10 (4.8)
Treatments prior to crizotinib
chemotherapy (%) 110 (80) 64 (74) 174 (77) 45 (22)
Baseline cns metastases 83 (61) 52 (60) 136 (60) 25 (12.1)
Follow-up period, months (min–max) 3.9–14.1 (primary)
8.7–18.9 (updated)
1.1–13.6 (primary)
1.1–19.9 (updated)
n/a 0.0–10.0
Abbreviations: cns, central nervous system; ecOg, eastern cooperative Oncology group; n/a, not applicable; nsclc, non-small-cell lung cancer.
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[Table 5]). Of the dose discontinuations, N=12 (41.4%) were 
due to disease progression, 9 (31.0%) were due to death, N=5 
(17.2%) were due to patient request, and N=3 (10.3%) were 
due to other reasons (none were due to adverse events).
safety and tolerability
There were no dose discontinuations or dose reductions due 
to adverse events among the patients in this study. Of the 
dose reductions, N=7 (3.38%) were due to adverse events; 
Table 3 Differences in best overall systemic response rate between clinical trial samples and the current study sample among those 
using alectinib post-crizotinib progression
Types of response rate Alectinib group 
in Ou et al28 
(response-evaluable 
population)
Alectinib group 
in Shaw et al29 
(primary analysis)
Pooled analysis 
in Yang et al30
Alectinib group 
in study sample
n 122 67 189 207
complete response (%) 0 (0.0) 0 (0.0) 0 (0.0) 14 (6.8)
Partial response (%) 61 (50.0) 35 (52.2) 97 (51.3) 125 (60.4)
stable disease (%) 35 (28.7) 18 (26.9) 52 (27.5) 47 (22.7)
Progressed disease (%) 22 (18.0) 11 (16.4) n/a 21 (10.1)
Unknown/indeterminate (%) 4 (3.3) 3 (4.5) n/a 0 (0.0)
Objective response rate (%) 61 (50.0) 35 (52.2) 97 (51.3) 139 (67.1)
Disease control rate (%) 96 (78.7) 53 (79.1) 149 (78.8) 186 (89.9)
Abbreviation: n/a, not applicable.
Table 4 Differences in best overall systemic response rate across patient characteristic strata among those using alectinib post-
crizotinib progression (n=207)
Characteristics N Complete 
response (%)
Partial 
response (%)
Stable 
disease (%)
Progressive 
disease (%)
P-value
Treatment setting 0.173
nonacademic 102 9.0 (8.8) 57.0 (55.9) 28.0 (27.5) 8.0 (7.8)
academic 105 5.0 (4.8) 68.0 (64.8) 19.0 (18.1) 13.0 (12.4)
Physician specialty 0.435
hematology/oncology 109 7.0 (6.4) 66.0 (60.6) 28.0 (25.7) 8.0 (7.3)
Medical oncology 98 7.0 (7.1) 59.0 (60.2) 19.0 (19.4) 13.0 (13.3)
age 0.576
,65 years 133 11.0 (8.3) 77.0 (57.9) 32.0 (24.1) 13.0 (9.8)
$65 years 74 3.0 (4.1) 48.0 (64.9) 15.0 (20.3) 8.0 (10.8)
race/ethnicity 0.001
White 113 11.0 (9.7) 68.0 (60.2) 25.0 (22.1) 9.0 (8.0)
asian 37 2.0 (5.4) 31.0 (83.8) 2.0 (5.4) 2.0 (5.4)
Other 57 1.0 (1.8) 26.0 (45.6) 20.0 (35.1) 10.0 (17.5)
smoking status 0.074
current smoker 24 2.0 (8.3) 12.0 (50.0) 4.0 (16.7) 6.0 (25.0)
Former/never/passive smoker 183 12.0 (6.6) 113.0 (61.7) 43.0 (23.5) 15.0 (8.2)
BMi 0.811
Underweight 6 0.0 (0) 3.0 (50.0) 2.0 (33.3) 1.0 (16.7)
normal 102 8.0 (7.8) 65.0 (63.7) 18.0 (17.6) 11.0 (10.8)
Overweight 80 5.0 (6.3) 48.0 (60.0) 20.0 (25.0) 7.0 (8.8)
Obese 19 1.0 (5.3) 9.0 (47.4) 7.0 (36.8) 2.0 (10.5)
cci 0.569
0 96 8.0 (8.3) 61.0 (63.5) 18.0 (18.8) 9.0 (9.4)
1 62 5.0 (8.1) 37.0 (59.7) 14.0 (22.6) 6.0 (9.7)
2+ 49 1.0 (2.0) 27.0 (55.1) 15.0 (30.6) 6.0 (12.2)
ecOg 0.009
0–1 102 7.0 (6.9) 66.0 (64.7) 25.0 (24.5) 4.0 (3.9)
2+ 10 0.0 (0) 3.0 (30.0) 3.0 (30.0) 4.0 (40.0)
Unknown 95 7.0 (7.4) 56.0 (58.9) 19.0 (20.0) 13.0 (13.7)
Prior chemotherapy 0.006
no prior chemotherapy 163 12.0 (7.4) 98.0 (60.1) 42.0 (25.8) 11.0 (6.7)
Prior chemotherapy 44 2.0 (4.5) 27.0 (61.4) 5.0 (11.4) 10.0 (22.7)
Abbreviations: BMi, body mass index; cci, charlson comorbidity index; ecOg, eastern cooperative Oncology group.
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specific adverse events included fatigue (N=4), hepatotoxic-
ity (N=2), bradycardia (N=1), and edema (N=1).
Discussion
The objectives of this study were to examine the real-world 
usage and clinical outcomes among patients with ALK+ 
NSCLC who were treated with alectinib after progressing on 
crizotinib as their first ALK inhibitor. The sample character-
istics of our study patients vs those of clinical trials patients 
emphasize the differences between these two environments. 
The alectinib sample in our study was ~10 years older, had 
fewer Asian respondents, more African-American and 
Hispanic respondents, had a more diverse histology (clinical 
trials were almost exclusively adenocarcinoma), had more 
current smokers, and had poorer functional status based on 
ECOG measures than clinical trial samples.28,29 Additionally, 
many alectinib patients were managed by a hematologist/
oncologist and in the private practice setting. Although not 
alectinib specific, recent real-world data studies of ALK+ 
NSCLC patients suggested similar demographic (age, sex) 
and health history (smoking status) findings as reported 
here.32,33 These results suggest that the patients prescribed 
alectinib immediately after crizotinib progression are more 
demographically diverse than those enrolled in clinical trials, 
which could have implications for clinical outcomes and 
experiences with safety/tolerability events.
Rates of brain metastases in our study vis-à-vis published 
literature deserve specific comment. Some real-world studies 
have reported brain metastatic rates over 50%,34 which is simi-
lar to that reported in clinical studies.28–30 However, other real-
world studies have estimated rates closer to 20%–30%.33,35–37 
These numbers are still higher than those reported in our 
sample in which 12% of patients had brain metastases at 
the end of crizotinib/initiation of alectinib. Although it 
is unknown what could cause the discrepancy, there are 
several possibilities. First, the follow-up time (as well as the 
timeframe that constituted “baseline”) was slightly shorter 
in the present study (eg, relative to Betts et al33); thus, there 
was less time for a brain metastasis to manifest. Secondly, 
our patient population was generally older than the available 
clinical data, and research has suggested that the incidence 
of brain metastases in older patients is lower than that in 
younger patients.38 Recent studies have suggested that only 
47% of brain metastases are symptomatic39 representing a 
possible source of underdiagnosis of brain metastases that is 
disproportionately more common in smaller practices than 
larger academic centers. Most of the patients in this study 
were treated in smaller private practices, which could have 
contributed to the lower rates of brain metastasis. Undoubt-
edly, more research is necessary, though substantial clinical 
data suggest the importance of brain metastases in the ALK+ 
NSCLC patient population.24,40
The observed response rates were generally similar in 
our study to clinical trial results and, to a certain degree, 
even more favorable.28–30 However, in some cases these 
response rates differed significantly by the characteristics 
of the patients. Asian patients (vs non-Asian/non-White 
patients), former/passive/never smokers (vs current smokers), 
and patients with better functional status (vs patients with 
poorer functional status), all reported better response rates. 
Nevertheless, it should be noted that for all strata, response 
rates were objectively high and, due to small sample sizes, 
caution should be exercised when interpreting the compari-
sons across groups. Further, the RECIST criteria were not 
used to define response in this real-world study; rather, the 
oncologist determined response based on information in the 
patient’s chart.
Finally, the results suggest that alectinib was well toler-
ated in real-world clinical practice. Discontinuation was 
relatively uncommon over the study period (14%) and 
when it occurred it was mostly due to disease progression; 
no discontinuation due to adverse events was observed. 
Dosage reductions and dosage interruptions were even less 
common. Fatigue was the most common safety/tolerability 
event that led to dose modifications. However, it should be 
noted that the observation time for our study (due to the recent 
availability of alectinib) was less than that in clinical trials 
(14–20 months for randomized controlled trials vs 10 months 
for our study; Table 2).
Limitations
Most of the research questions were descriptive in nature, 
without clear threats to internal validity. However, the 
Table 5 Frequency and reasons for dosage modification among 
patients using alectinib post-crizotinib progression (n=207)
Modification 
category
Reason N (%)
Discontinuation 
(n=29; 14.0%)
Disease progression
Death
12 (41.4)
9 (31.0)
Patient request 5 (17.2)
Other 3 (10.3)
Dose reduction 
(n=9; 4.3%)
Toxicity
Disease progression
7 (77.8)
1 (11.1)
Patient request 1 (11.1)
Dose interruption 
(n=1; 0.5%)
Patient request 1 (100.0)
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method and the nature of the sample source may be a threat 
to the external validity. Only members of an Internet panel 
were eligible to join; these physicians (and, by extension, 
perhaps their patients) may differ from broader oncologist 
population. The selected panel did have a large representa-
tion with the intent to minimize this bias. Another threat to 
validity was the chart selection method. Although physicians 
were asked to select their most recent patients, physicians 
could have selected charts preferentially, which may have 
biased the sample of patients. Finally, the RECIST criteria 
were not used to determine response to treatment in this 
real-world study.
Conclusions
This retrospective chart review study is the first to document 
the real-world usage and clinical outcomes of patients with 
ALK+ NSCLC who are treated with alectinib after experi-
encing progression on crizotinib as their first ALK inhibitor. 
Substantial differences were observed between the real-world 
sample and the samples of alectinib clinical trials; our study 
suggested (consistent with other real-world data studies 
on ALK+ NSCLC patients more broadly31,32) that patients 
using alectinib in clinical practice are older, more racially/
ethnically and histologically diverse than those samples in 
published trials. Nevertheless, response rates are generally 
high and similar to those reported in clinical studies, though 
there is some variation by patient characteristics. In addi-
tion, alectinib was well tolerated in clinical practice with 
no discontinuations or dose interruptions and very few dose 
reductions due to adverse events.
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